SELLAS Life Sciences Group, Inc. SLS R2KR3KPHARMA
Company Overview
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -100.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | -100.00% |
Stock Price Performance
| 1 Year: | +794.19% |
| 6 Months: | +150.63% |
| 3 Months: | +68.41% |
| 1 Month: | +18.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)54.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SLS SELLAS Life Sciences Group, Inc. R2KR3KPHARMA | 13.86 | -60.26 | $2.73B | 0.00% | -39.64% | -43.59% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Dec 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 5.70M | 1.90M | 0 | 1.00M | 0 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | - |
| Gross Profit | 2.91M | 1.45M | 1.23M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -7.99M | -6.89M | - | -11.85M | -15.78M | -10.57M | -8.91M | -9.08M | -8.63M | -8.97M | -9.29M | -6.47M | -5.09M | -4.91M | -4.46M | - | - | - | - | - | - | -4.06M | -4.27M | -4.49M | -2.25M | -4.45M | -6.98M | -16.73M | -8.62M | -7.15M | -11.28M | -9.05M | -9.36M | -9.64M | -7.62M | -7.33M | -6.06M | -6.87M | -7.08M | -9.25M |
| Net Income | 5.39M | -6.93M | -5.52M | -2.54M | -19.94M | -6.17M | -10.54M | -15.66M | -18.03M | -16.49M | 5.39M | -6.93M | -4.60M | -5.91M | -4.46M | -8.00M | -6.06M | -290.00K | -4.54M | -3.13M | -4.20M | -4.14M | -4.42M | -4.47M | -2.40M | -4.61M | -7.08M | -16.74M | -8.41M | -7.02M | -11.10M | -8.84M | -9.27M | -9.57M | -7.47M | -7.11M | -5.81M | -6.60M | -6.79M | -8.41M |
| Diluted EPS | -0.11 | - | - | - | - | - | - | - | - | - | 0.58 | - | - | -0.22 | - | - | - | - | - | - | - | - | -0.66 | -0.53 | -0.16 | -0.30 | -0.45 | -1.05 | -0.41 | -0.34 | -0.47 | -0.31 | -0.33 | -0.21 | -0.13 | -0.10 | -0.07 | -0.07 | -0.06 | -0.05 |
| R&D Expense | 5.28M | 3.63M | - | 6.77M | 8.07M | 7.03M | 5.83M | 7.20M | 5.74M | 5.44M | 6.17M | 3.62M | 2.18M | 1.83M | 1.07M | 1.80M | 1.59M | 1.72M | 1.86M | 1.38M | 1.80M | 1.86M | 2.28M | 2.37M | 4.28M | 3.46M | 4.54M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 2.49M | 9.32M | - | - | - | - | 0 | 1.90M | 7.60M | 1.00M | 0 | - | - |
| Operating Income | - | -12.49M | -21.20M | -28.49M | -43.90M | -34.22M | -15.99M | -23.04M | - | -20.04M | -16.98M | -25.29M | -41.95M | -37.87M | -31.51M | -28.27M |
| Net Income | -11.99M | -11.48M | -34.97M | -76.68M | -36.61M | -63.90M | -17.68M | -23.75M | -27.67M | -19.29M | -16.76M | -20.70M | -41.30M | -37.34M | -30.88M | -26.86M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -2.11 | -1.34 | -2.13 | -1.34 | -0.50 | -0.25 |
| R&D Expense | 7.87M | 3.85M | 14.61M | - | - | - | 11.39M | 6.07M | 8.77M | 7.29M | 9.28M | 15.67M | - | - | - | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.48M | 30.97M | 54.99M | 87.98M | 80.49M | 82.14M | 6.42M | 33.53M | 16.91M | 16.61M | 46.05M | 26.27M | 20.94M | 6.22M | 19.43M | 78.34M |
| Total Equity | - | 2.43M | 10.11M | 27.76M | 5.89M | 37.06M | -12.26M | -5.00M | 2.07M | 5.25M | 6.09M | 27.96M | 20.35M | 4.85M | -7.98M | 9.46M | 70.87M |
| Cash & Equivalents | 5.68M | 6.89M | 47.79M | 32.81M | 47.79M | 23.65M | 1.40M | 5.96M | 2.32M | 5.34M | 7.28M | 35.30M | 21.36M | 17.12M | 2.53M | 13.89M | 71.79M |
| Long Term Debt | - | - | - | 0 | 7.74M | 4.49M | 0 | - | 2.61M | 0 | - | - | - | - | - | - | - |
| Total Liabilities | - | 5.05M | 20.86M | 27.23M | 82.09M | 43.43M | 68.63M | 11.42M | 31.46M | 11.67M | 10.52M | 18.09M | 5.93M | 16.09M | 14.20M | 9.97M | 7.47M |
| Current Liabilities | - | 5.03M | 11.20M | 15.92M | 62.47M | 27.23M | 57.07M | 5.76M | 24.57M | 5.97M | 5.29M | 12.34M | 4.98M | 15.52M | 13.73M | 9.51M | 7.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -10.26M | -14.67M | -20.97M | -28.93M | -42.87M | -48.16M | -11.85M | -10.99M | -30.42M | -17.64M | -10.42M | -26.02M | -23.81M | -31.41M | -35.40M | -28.39M |
| Investing Cash Flow | -106.00K | 14.00K | -87.00K | -12.04M | -5.53M | 10.39M | -85.00K | 12.16M | 0 | - | - | 0 | -4.50M | -5.50M | 0 | - |
| Financing Cash Flow | 11.57M | 19.20M | 42.43M | 55.95M | 24.26M | 43.84M | 16.50M | 5.53M | 23.12M | 19.57M | 38.44M | 12.07M | 24.08M | 22.32M | 46.76M | 86.30M |
| Capital Expenditure | -106.00K | -53.00K | - | -320.00K | -57.00K | -153.00K | -6.00K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -10.36M | -14.72M | - | -29.25M | -42.93M | -48.31M | -11.86M | - | - | - | - | - | - | - | - | - |
| Share Buybacks | 3.85M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - | - | - | 0 | 487.00K | 0 | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | -1,145.5% | -471.1% | - | - | - | - | - | -893.8% | -332.8% | -4,195.0% | - | - | - |
| Net Margin % | - | - | - | -3,083.2% | -392.8% | - | - | - | - | - | -881.9% | -272.4% | -4,130.1% | - | - | - |
| ROE % | -493.5% | -113.6% | -126.0% | -1,302.7% | -98.8% | 521.1% | 353.8% | -1,147.5% | -527.6% | -316.6% | -59.9% | -101.7% | -851.4% | 468.2% | -326.3% | -37.9% |
| ROCE % | - | -63.2% | -54.3% | -111.7% | -82.4% | -136.5% | -2,415.1% | -257.2% | - | -177.1% | -50.4% | -118.8% | -772.8% | 503.8% | -317.6% | -39.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.46% | 15.07M | $199.08M |
| 2 | State Street Corporation | 6.44% | 13.00M | $171.68M |
| 3 | Vanguard Capital Management LLC | 4.07% | 8.23M | $108.67M |
| 4 | Geode Capital Management, LLC | 2.42% | 4.88M | $64.52M |
| 5 | Anson Funds Management LP | 2.23% | 4.50M | $59.45M |
| 6 | Jones Financial Companies, L.L.L.P. | 1.14% | 2.30M | $30.44M |
| 7 | Vanguard Portfolio Management LLC | 1.07% | 2.16M | $28.55M |
| 8 | Susquehanna International Group, LLP | 1.02% | 2.05M | $27.09M |
| 9 | Northern Trust Corporation | 0.80% | 1.62M | $21.40M |
| 10 | Vanguard Fiduciary Trust Co | 0.66% | 1.34M | $17.64M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SLS
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance - Stocktwits
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQRGwxNzR3cXI3LVhWcmNHTFV3ZlR2Q1BJVTBBci1LMW83TUdEejAtZW55YzlfTXVTSG9VU3pvX3kwMGtGUkNCejd4cDV4V3ZiMWxodTFsUzhldUpMWEF1OGRqZ0poSnp6Zjh0MmM0OXQzejFDckVJOFRTSXk4dVZERTBYb28tWl8yYk1Ldk…
SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxOQVZZRjNRNlBvV29DWE1JYXFMU0Q5NHpibXNzNkVNc2FCYUlCdV8yVjdYYURoakw3VGttQ2xyRUdjNzFMUWNERFNkZTVZT0s5c3FPRy12ME5xNDlRNGtfbG8xNGVYUWc3SWRybmlkbVJYOEk1eW5Pd25QRk0weHpXbmJlS3lNS0RjVTFfY0…
SLS Stock Rises Overnight: Healthcare Execs Tout AML Drug As ‘Game Changer’ Ahead Of Final Trial Trigger - Stocktwits
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxNRERzaS0yUkRvcXpWWDRQN3Q4aHVkQVI1VlNPRHVseUdQTkEwUkxqQ1NidDc3Z25pT2F5Z2VDZExydXJjSGItcUxvdTlLaXhwc3Zxd0kxbzVZSXl3enNTejJCVXgyTHN6Z015ZHBSSk95MkNDTEJNbVBsRWU4NG9ueUFfUmxFazJNSG1QaE…
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED) - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQdWRWd0VCQi1HeExzYllrT1RnLUpSeVZseVdfODlYWU1RT25faVdPQUhQYjdUMmZMcjVHWjM3Q1ZpdFVrUE1NejdHU3I5TkpHcWJVQTZPeXJfZXVBN0VnQ2lRcG1GY0FRWlJnS1llVXc1VDhCRk1PYXlyX0p1UnRmYV9NdTRmZEE1ZnMxMV…
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxObnhvZzhxaDA2VTN5Q1lrOVRRMkdhMl9KcUJXLWItd0Y3UW51bjE3WllHTk8xVmNTYnhISTlOYTE5UVVndVVHMkU4OEYyV0FwQW85RHp4OENmWXhJemhUQmc2N3pFTW5JR01TcGFtdnExNGRLVTBQbm5oaDVrVzRrSmxfaU9rQUk5djNYRH…
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNaVBtRjdCUUVRX0JKekNNYzdOUkhwX0ZKa3hQNHgzM3F0Z1JlajUyVVU4N3kzR0U3N0xGZHh6WlpOWjVLODR6RGRhY3BfeDFYNGtlRGYwQ3N6UUU4d3dRUWFaWnhLSnd5TlJMVWo3NEVlZEdCc3hZUE5VNHpCaUdFazlNMGVRb1BZLVF6em…
SLS — Frequently Asked Questions
What is the current share price of SELLAS Life Sciences Group, Inc. (SLS)?
As of 2026-09-07 16:24 PDT, SELLAS Life Sciences Group, Inc. (SLS) trades at $13.86 on NasdaqCM. Its 52-week range is $1.39 to $15.46.
What is the market capitalisation of SLS?
SELLAS Life Sciences Group, Inc. (SLS) has a market capitalisation of $2.73B on NasdaqCM.
What is the P/E ratio of SLS?
SLS trades at a trailing price-to-earnings (P/E) ratio of -60.26. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 20.29.
What is the return on equity (ROE) of SLS?
SLS has a return on equity (ROE) of -43.59%. Its return on capital employed (ROCE) is -39.64%.
Is SLS a good stock to buy?
This page provides a data-driven analysis of SELLAS Life Sciences Group, Inc. (SLS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.